COMP <GO>
ARWR vs LLY // FREE CASH FLOW YIELD
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ARWR 3
— LLY 10
▲ FREE CASH FLOW YIELD LEADER: LLY
LAST: $59.57 (-0.55%) • MKT CAP: $8.41B
fcf-yield
1.84%
LAST: $1,410.99 (-0.46%) • MKT CAP: $1.33T
fcf-yield
2.31%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | 32.36% | -21.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | 36.2x | +37.57 | LLY | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 1.84% | 2.31% | -0.47 | LLY | /fcf-yield <GO> |
| Operating Margin | 11.90% | 40.21% | -28.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 31.90% | -32.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 45.51% | +134.49 | ARWR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 9.25 | -2.65 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.55% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.2 | 70.6 | -30.40 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.51 | +0.45 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 30.6x | -12.62 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.41B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | LLY REV | ARWR GROSS % | LLY GROSS % | ARWR FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $65.18B | — | 83.0% | $156.9M | $16.81B |
| FY 2024 | $3.6M | $45.04B | — | 81.3% | -$604.3M | $8.82B |
| FY 2023 | $240.7M | $34.12B | — | 79.3% | -$164.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
LLY // BETA 0.51